CAR-T in vivo persistence is a key factor in determining CAR-T function,47 which relies on an appropriate strength of tonic signaling.14 Two types of CARs, CD19 and CD22, currently being used to target hematologic malignancies, exhibit weak tonic signals. Here, CD22 is linked to hematologic disorder.